To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Eculizumab
Eculizumab (rINN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.[1] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007. Additional recommended knowledgeEcuilzumab exibits it's theraputic activity by bind to the 2b subunit of the C5 convertase enzyme. C5 convertase is produced by the binding of subunits C4b,C2b and C3b on the surface of the bacterium. Binding of Eculizumab to the 2b subunit, results in the reduction of the esterase activity of this subunit, therefore C5 convertase cannot hydrolysize C5 into C5a & C5b subunits respectively.
Categories: Monoclonal antibodies | Orphan drugs |
||||||||||||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Eculizumab". A list of authors is available in Wikipedia. |